[go: up one dir, main page]

WO2003028645A3 - Nouvelles compositions de carvedilol - Google Patents

Nouvelles compositions de carvedilol Download PDF

Info

Publication number
WO2003028645A3
WO2003028645A3 PCT/US2002/031123 US0231123W WO03028645A3 WO 2003028645 A3 WO2003028645 A3 WO 2003028645A3 US 0231123 W US0231123 W US 0231123W WO 03028645 A3 WO03028645 A3 WO 03028645A3
Authority
WO
WIPO (PCT)
Prior art keywords
carvedilol
novel compositions
composition
novel
angina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/031123
Other languages
English (en)
Other versions
WO2003028645A2 (fr
Inventor
Vlassios Andronis
Choon K Oh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to AU2002341901A priority Critical patent/AU2002341901A1/en
Publication of WO2003028645A2 publication Critical patent/WO2003028645A2/fr
Publication of WO2003028645A3 publication Critical patent/WO2003028645A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle composition à base de carvedilol et des méthodes d'utilisation de ladite composition pour traiter l'hypertension, l'insuffisance cardiaque congestive et l'angor.
PCT/US2002/031123 2001-10-01 2002-10-01 Nouvelles compositions de carvedilol Ceased WO2003028645A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002341901A AU2002341901A1 (en) 2001-10-01 2002-10-01 Novel compositions of carvedilol

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32636701P 2001-10-01 2001-10-01
US60/326,367 2001-10-01
US33023401P 2001-10-18 2001-10-18
US60/330,234 2001-10-18

Publications (2)

Publication Number Publication Date
WO2003028645A2 WO2003028645A2 (fr) 2003-04-10
WO2003028645A3 true WO2003028645A3 (fr) 2004-03-25

Family

ID=26985374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031123 Ceased WO2003028645A2 (fr) 2001-10-01 2002-10-01 Nouvelles compositions de carvedilol

Country Status (2)

Country Link
AU (1) AU2002341901A1 (fr)
WO (1) WO2003028645A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261355A1 (en) 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
NZ537161A (en) 2002-06-27 2007-09-28 Sb Pharmco Inc Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
WO2005051383A1 (fr) 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Sels de carvedilol, compositions correspondantes, procedes d'administration et/ou de traitement
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
US20080138404A1 (en) * 2006-12-06 2008-06-12 Biovail Laboratories International S.R.L. Extended release formulations of carvedilol
AR132658A1 (es) * 2023-05-11 2025-07-16 Catalent Uk Swindon Zydis Ltd Aumento de la permeación para la absorción pregástrica de ingredientes farmacéuticos activos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6224909B1 (en) * 1996-09-12 2001-05-01 Roche Diagnostics Gmbh Fast decomposing pellets
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6224909B1 (en) * 1996-09-12 2001-05-01 Roche Diagnostics Gmbh Fast decomposing pellets
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof

Also Published As

Publication number Publication date
WO2003028645A2 (fr) 2003-04-10
AU2002341901A1 (en) 2003-04-14

Similar Documents

Publication Publication Date Title
WO2002065834A8 (fr) Nouvelles formulations de carvedilol
WO2003035617A3 (fr) Derives de l'uk-2a
TNSN03083A1 (en) Mercaptoacetylamide derivatives, a process for their preparation and their use
WO2004033659A3 (fr) Nouveau gene suppresseur de tumeur, compositions et leurs procedes de fabrication et d'utilisation
WO2003006425A3 (fr) Nouveaux composes convenant comme anti-inflammatoires, immuno-modulateurs et anti-proliferants
WO2003070182A3 (fr) Bloqueurs de canaux sodium
WO2003070184A3 (fr) Bloqueurs de canaux sodium
WO2005051322A3 (fr) Base libre de carvedilol, ses sels, formes anhydres ou solvates, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et procedes de traitement ou d'administration
WO2001079460A3 (fr) Polypeptides a activite haloperoxydase
WO2002072865A3 (fr) Procedes, kits et compositions se rapportant a des oligomeres de combinaison, et bibliotheques permettant leur preparation
EP1283235A3 (fr) Composition, méthode de fabrication et méthode d'utilisation de la composition adhésive
WO2003082857A3 (fr) Polymorphes de lansoprazole et procedes de preparation de ces derniers
WO2004075857A3 (fr) Preparations, combinaisons, et procedes de traitement de pathologies cardio-vasculaires et autres etats associes
CA2470809A1 (fr) Derives de 6-aminomorphinane et methode de production et utilisation connexes
WO2003033557A3 (fr) Copolymeres fluores, leur production et leur utilisation
WO2003062443A3 (fr) Composes alcanes substitues et utilisations associees
WO2003028645A3 (fr) Nouvelles compositions de carvedilol
WO2004111047A3 (fr) Cycloalkanepyrrolopyridines utilisees comme antagonistes du recepteur dp
WO2003000893A3 (fr) Acides nucleiques codants pour des recepteurs couples a une proteine g
AU2003201163A1 (en) Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol
AU2002358856A1 (en) Novel artemisinine derivatives, and uses thereof for treating malaria
MXPA04003910A (es) Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
WO2003092622A3 (fr) Monocitrate monohydrate de carvedilol
WO2004026892A3 (fr) Fragmentation d'adn
AU2002341924A1 (en) Novel composition of carvedilol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP